[go: up one dir, main page]

WO2017223090A1 - Vaccin à base de cellules complètes contre le virus zika - Google Patents

Vaccin à base de cellules complètes contre le virus zika Download PDF

Info

Publication number
WO2017223090A1
WO2017223090A1 PCT/US2017/038340 US2017038340W WO2017223090A1 WO 2017223090 A1 WO2017223090 A1 WO 2017223090A1 US 2017038340 W US2017038340 W US 2017038340W WO 2017223090 A1 WO2017223090 A1 WO 2017223090A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
antigen
composition
virus
subject
Prior art date
Application number
PCT/US2017/038340
Other languages
English (en)
Inventor
Gavreel Kalantarov
Ilya Trakht
Original Assignee
The Trustees Of Columbia University In The City Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of Columbia University In The City Of New York filed Critical The Trustees Of Columbia University In The City Of New York
Publication of WO2017223090A1 publication Critical patent/WO2017223090A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present disclosure relates to -methods ' and compositions !bftfee- prevention and/or treatment of iavivita infection.
  • the -present disclosure relates to whole-ceil vaccine compositions that trigger protective immunity against Zika virus infection.
  • the presen t disclosure provides Cor an in iimoge»kt-o.ti ⁇ sition om iismg.: cel ls (i) comprising at least one flavivirus antigen (e.g.;, at least one Zika virus antigen), aud (ii)
  • cel ls comprising at least one flavivirus antigen (e.g.;, at least one Zika virus antigen), aud (ii)
  • the present disclosure also provides for an immunogenic composition
  • an immunogenic composition comprising; a first population of cells comprising at least one fJavivtrus antigen (e.g., at least one Zika virus antigen), and a second population of cells expressing at least one cytokine.
  • fJavivtrus antigen e.g., at least one Zika virus antigen
  • the present disclosure provides for a method of preventing or treating itavivirus infection (e.g via ika vims infection) in a subject, the method comprising administering to the subject an imnnniogenie composition comprising; cells (i) eoniprising at least one tlaviviras antigen. (e.g. s at least on Zika vims antigen), and (ii) expressing at least one cytokine.
  • itavivirus infection e.g. ika vims infection
  • an imnnniogenie composition comprising; cells (i) eoniprising at least one tlaviviras antigen. (e.g. s at least on Zika vims antigen), and (ii) expressing at least one cytokine.
  • the present di sc losure provides for a method of preventing or treating 3 ⁇ 4vi virus infection (e.g. , .Zika virus, infection) in a subject, lite method comprising administering to the subject am immunogenic composition comprising ; a first population of cells comprising at least one fl.a.vi vims antigen (e,g. , at least one Zika virus antigen), and a second populatio of cells
  • 3 ⁇ 4vi virus infection e.g. , .Zika virus, infection
  • lite method comprising administering to the subject am immunogenic composition comprising ; a first population of cells comprising at least one fl.a.vi vims antigen (e,g. , at least one Zika virus antigen), and a second populatio of cells
  • the present disclosure provides tor a method of preventing or if ating 3 ⁇ 4vivirus infection (e.g,, Zika vires infection) in a subject, the method comprising: (a) adniinistering to the subject ' a first population of cells comprising at least one flavi virus antigen (e.g., at least one Zika virus antigen), and (b) administering to the subject a second population of cells expressing at least one cytokine.
  • 3 ⁇ 4vivirus infection e.g, Zika vires infection
  • the first population of cells and the second population of cells are of the same type of cells, in certain embodiments, the first population of cells and the second population of cells ate of different, types of cells.
  • Non-limiting examples of flavivierises include Zika virus, the dengue vims (DEHV), the yellow fever virus (YFV), the West Nile virus (WNV), the Japanese encephalitis virus (JHV), the St. Louis encephalitis virus, and the tick-borne encephalitis virus.
  • DEHV dengue vims
  • YFV yellow fever virus
  • WNV West Nile virus
  • JHV Japanese encephalitis virus
  • St. Louis encephalitis virus the St. Louis encephalitis virus
  • tick-borne encephalitis virus tick-borne encephalitis virus.
  • the subject may be a woman. In certain embodiments * the subject is a. woman who is pregnant.
  • Mouse neuroblastoma cell line N2a was transfeeted. with pcD ' A- 3.1 vector containing mouse GM «CSF gene. The transfeeted cells -were designated as N2a* GM.SCF or N2a-GM.
  • N2a-GM cells- were then Infected with ZIKV strain M 776 (Uganda). Viral infection was monitored b staining viral E2 protein using ant-E2 antibodies 4G2.
  • Figures I A and IB cell having an infecfiviiy rate of about 40% - 50%.
  • Figures IC and ID cells having an inactivity rate of about 80% ⁇ 9Q%,
  • Figure 2 shows results from the cellular e y ne-iinked imffiimoso b nt assay (cELISA) assay, Sera from ice immunized with 2a-GM (naive) cells did not react either with N2a-GM (naive) Cells ("Group 1 on N2A ⁇ GM ⁇ n ive") o with. N3 ⁇ 4-GM-Z1 V cells ("Group 1 on N2A-GM- Z1KA").
  • mice vaccinated with N2a-GM-ZIKV ceils was immunologically reactive to N2a ⁇ GM ⁇ ZlKV cells ("Group 2 on K2A-GM ⁇ Zfi A"), but not reactive to N2a. ⁇ GM ceils ("Group 2 on M2A ⁇ G -iiaive").
  • Figure 3 shows antibody response (vertical bars according toibe lefr y ⁇ a3 ⁇ 4s s cELISA assay on N2a-G - iiK-V cells) and antibody neutralization potential (solid line with closed circles, according to the .tight y-axis, PENT) for three groups of mice irmiianized with N2a-GM-ZIKV cells (group Ah ] 2a ⁇ ZlKV cells (group B), or -purified ZIKV (group C), respectively.
  • Figure shows antibody response (vertical bars according to the left y-a>ds > cELISA assay on H2a ⁇ GM-ZIKV cells) for, as well as- t e number of colonies infected, with Z V in the presence of a fixed dilution (1 :3000) of the serum (solid line with closed circles, according to the right y- axls) from * three groups of mice immunized with N2a-GM-ZIKV cells (group A), N2a ⁇ ZiKV ceils (group B), or purified ZIKV (group € ⁇ , especti el *
  • Figures 5A-5KL Testing ZIK infectivity in di fferent cell types Different types of cells, including Vero cells ( Figures 5A and 5B) ; ' M2a (naive) ceils ( Figures 5A and 5B), N2a ⁇ GM €SF cells ⁇ (Figures.5E a d 5 ⁇ Nl new cell Mae ( Figures SO and 53 ⁇ 4), humarr fibroblasts WS-1 ( Figures Si and SJ human fibroblasts PCS201. ⁇ 012 ( Figure 5K), were infected with ZIKV- containing cell cultute media (P.2) aad imniunostained using anii-E2 antibodies 4G2 at different time points post-kfectioa, e.g., 24 hours, or 48; tars post-infection.
  • Figures 5A, 5C, SB, SG, and 51 show celfe 24 hours post-infection.
  • the present disclosure provides methods and compositions for the prevention arid/o treatment of Zika virus infection; 1» certai embodiments, die inm notherapy uses cells comprisin Zika virus antigens and expressing a cytokine, sucit as granulocyte macrophage- colony-stimulating factor (GM-CSF),. in. certain embodiments, the present disclosure relates to immunotherap using cells comprising Zika virus antigens nd cells expressing a cytokine, such as GM-CSP. The immunotherapy induces or enhaaces immune responses against Zika viruses.
  • GM-CSF granulocyte macrophage- colony-stimulating factor
  • di present disclosure relates to compositions a d to methods for inducing o enhancing an immune response to a fiavi virus antigen (e,g a Zika virus antigen ⁇ .
  • a fiavi virus antigen e,g a Zika virus antigen ⁇ .
  • An. immune response to the target antigen may provide a prophylactic or therapeutic effect.
  • Viral infections can be treated and or prevented by administering reagents that modulate the immune system
  • the present compositions and methods inhibit and/or treat the ilavivirus infection (e.g. * Zika. vims infection), and/or ameliorating on or more symptoms associated wit the ilavivirus infection (e.g., Zika virus infection).
  • the present compositions and methods are useful in the prophylaxis and/or treatment of a disease caused by flavivifuses (e.g., Zika viruses).
  • An appropriate cell expressing at least ne virus antigen e.g., cell comprising at least one inactivated or attenuated virus
  • the antigen and the cytokines may he administered without a host cell to a subject (e.g., as cell lysate).
  • the present composition can be administered to a subject infected by the viruses to treat the viral infection.
  • the present composition and method relate to a whole cell-based vaccine composition.
  • the present whole cell vaccine composition provides multiple antigens that can be targeted by both the innate and adaptive immune systems.
  • the present whole-cell based vaccine serves as an adjuvant on its own, because of their abilit to- s imulate the immu e system in a non-specific manner .
  • the present whole-cell vaccine comprises allogeneic cells providing MHC ⁇ allotypes (alternative histocompatibilit complexes)* which are powerful stimulators of the i mune res onse
  • the present wnole cell-based vaccine offers a minrai delivery of viral antigens to antigen presenting cells (APC as the primary recognition of infectious agents involves recognitio of infected cells, rather than individual ' viral particles.
  • the present composition and method deliver both GM-CSF and inactivated Zifca virus to a subject, an therefore, esta lis both bnmoral as well as cellular immunity against Zifc vims antigens in a subject.
  • the present disclosure provides for an .immunogenic composition
  • ceils comprising at least, one ilaviviiiis antigen or a fragment thereof (e.g., at least one Zika virus antigen or a fragment thereof), wherein, the cells also express a cytokine (such a GM-CSF).
  • a cytokine such as a GM-CSF
  • the present disclosure provides fo an immunogenic composition comprising: cells (i) comprising at least one lavivirus antigen (e,. . > at least one Zifca virus antigen), and (ii) expressing at least one cytokine.
  • lavivirus antigen e,. . > at least one Zifca virus antigen
  • the present disclosure provides for an immunogenic composition
  • a first population of cells comprising at least one fla viviros antigen (e.g. at least one Zifca vims antigen) or a fragment thereof, and second populatio of cells expressing at least one cytokine (such as GM-CSF).
  • fla viviros antigen e.g. at least one Zifca vims antigen
  • second populatio of cells expressing at least one cytokine such as GM-CSF
  • ceils that express a cytokine e.g., GM-CSF
  • cells that comprise at least one ilaviviras antigen e ⁇ g., at least one Zifca virus antigen
  • at least one ilaviviras antigen e ⁇ g., at least one Zifca virus antigen
  • ilaviviras antigen such as inactivated ilaviviras, e.g., inactivated Zika vims
  • cells that express at least one cytokine such as GM-CSF
  • cells that comprise at least one jlavlvifns antigen e.g., at least one Zifca vims antigen) ' ⁇ such as inactivated flavivlrns, e.g., inactivated Zika virus
  • the ratio of t he n umber of the first population cells compri sing at least one flavivirt!s antigen (e.g., at least one Zika virus antigen) to the number of the second population of eel Is expressing at least one cytokine may range from about 50: 1 to about I ; 10, 40: 1 to about ⁇ ⁇ 30: 1 to about 1:6, 20:1 to about 1 :5 > 20:1 to about 1 :3, from about 20: 1 to about 1 :2, from about 15:1 to about 1:1.5, f om about 10:1 to about 1 :1, f om about 8:1 to about 1 : 1, from about #: 1 to about 1 :2, from about 5; 1 to about 1 : 1 , rom about 4 1 to about 1 : 1, from about 3:1 to about 1: 1 , from: about 2:1 to about 1:1, fcorn about 1.5:1 to about 1:1, from about 0.8:1 to about 1 :1 , from about 0,6
  • the eel! may comprise at least one virus antigen, or may comprise nucleic acids encoding at least one virus antigen.
  • th cell com rise at least one inactivated vims.
  • the present composition and method use the irradiated whole- cell pancreatic vaccine (G VAX) which is a vaccine derived from human pancreatic cell l ines (PANG 6.03 and PANC 10.05).
  • G VAX irradiated whole- cell pancreatic vaccine
  • Pancreatic GVAX has been genetically imodifieti to secrete human granulocyte maerophage-eolony stimulating factor (GM-CSF), an immune-raoduiatory cytokine that can activate antigen presenting cells (APCs, monocytes, and DCs) locally at the vaccine site (Dranolf et ai Inimnnoj.
  • GM-CSF granulocyte maerophage-eolony stimulating factor
  • APCs antigen presenting cells
  • monocytes monocytes
  • DCs antigen presenting cells
  • the cell may express the cytokine.
  • the cell may express and secret the cytokine:.
  • Non- l it iting examples of cytokines thai may be used i the presen t composition and method include GM-CSF, 1L ⁇ 2 ? 1L-4 S TNF-alpha, 1L ⁇ 6 ? CD2, JCAM * and combinations thereof In one
  • the cell expresses GM-CSF
  • the present disclosure provides for an immunogenic composition comprising: cells (i) comprising at least one fiavivifns antigen (e.g., at least one Zika vims antigen), and (ii) expressing at least one immunomodulatory molecnle *
  • the present disclosure provides for an imnmnogenie com ositi n comprising a first ' population of cells com risin at least one fiavf virus antigen (e * g., at least one 2ika virus antigen), and second population of cells expressing at least one immunomodulatory molecule.
  • the nrnnunomo uktory molecule can be a rec m i iaut o in cytokine, chemokrae, o iRiojanostimiil toiy' agen or nucleic acid encoding ' .cytokines, diemokines, or immimostimulstory agents designed to enhance the immunologic response.
  • Nonrlimitmg examples of immunornodutatory .cytokines include interferojxs (e.g., IFN- ⁇ » iFN-fi and IFK-y), intetleufcins (e.g., ti-i, TL-2 5 IL-3, 1L-4, IL-5, IL-6, IL-7, IL-S, lL-9, 1L- 10, 11-12, IL-!SJL ⁇ O, and IL ⁇ 2 i), tumor necrosis factors (e.g., TNF-a and TNF ⁇ f ).
  • interferojxs e.g., IFN- ⁇ » iFN-fi and IFK-y
  • intetleufcins e.g., ti-i, TL-2 5 IL-3, 1L-4, IL-5, IL-6, IL-7, IL-S, lL-9, 1L- 10, 11-12, IL-!SJL
  • erytlrro oieri EQ
  • FLT-3 ligand FLT-3 ligand
  • glp!O glp!O
  • ' TCA-3 MCP- M!F
  • ⁇ ⁇ ⁇ - ⁇ Rantes
  • M-CSF macrophage colony stinmdating factor
  • G-CSF granulocyte colony stimulating factor
  • GM-CSF granulocyte-macrophage colony stimulating factor
  • chemokises include, but are not limited to, Mi lu, Mip- ⁇ , Mip-3fc (Larc), ⁇ -3 ⁇ .
  • ⁇ mmun ge ic composition and "vaccine composition” are lnierchan»eable.
  • the cells may be proliieration-incompeient.
  • methods may be used to inactivate cells to make them incapable of ceil division but retaining the abilit to express cytokines.
  • the cells ma be unable to u er o mitosis, hut still retain the capability to express proteins such as cytokines.
  • Cells may be inactivated by tendering them proliferation incompetent by irradiation.
  • a dose ranging from about 3500 rads to about 30,000 tads is used to irradiate cells, in certain embodiments, methods such as treatments with mitomycin C , cy cloheximi.de, and analogous agents, and/or incorporat i o of a suicide gene by the cell etc. are used to render the cells prolifeatiou-iucompetent.
  • ce ls are ren ere prolifer tion incompetent by irradiation prior to adrainistraiion to the subject.
  • the present compos tion may ' elicit T-cel!, and/or B-ceiL, responses against a flavivirus.
  • the present vaccine composition can be used for prevention and/or treatment of flavivit-us infections (e.g., Zika. virus infections). Additionally, vaeetne(s) of the present disclosure can be used to prevent flavivirtts infection (e.g., Zika virus infection) of a fetus during pregnancy, For example, administration of vaccine to a woma before and/or during pregnancy can pre vent flavi virus infection (e.g. , Zika vims infection) of a fetus.
  • flavivirtts infection e.g., Zika virus infection
  • administration of vaccine to a woma before and/or during pregnancy can pre vent flavi virus infection (e.g. , Zika vims infection) of a fetus.
  • she present disclosure panicles a metho of preventing and/or treating Bavivirus infection (e,g ⁇ > Zika virus infection) in a subject, the method comprising tire step of administering t the subject a vaccine composition comprising: cells (i) comprising at least one flaviviras antigen (e.g.,,, at least one Zika virus antigen), and (ii) expressing at least one cytokine,
  • the present disclosure provides a method of preventing and/or treating .flavivinis infection (e.g., Zika vims infection) in a subject, the method comprising the step of ' administering to the subject vaccine composition compri sing; a first population of cells .comprising at least one flavi virus antigen (e.g., at least one Zika virus antigen ⁇ and a second population of ceils expressing at least one cytokine.
  • .flavivinis infection e.g., Zika vims infection
  • the method comprising the step of ' administering to the subject vaccine composition compri sing; a first population of cells .comprising at least one flavi virus antigen (e.g., at least one Zika virus antigen ⁇ and a second population of ceils expressing at least one cytokine.
  • my present disclosure provides a method of eliciting an imiaftae response to a flaviyirus (e,g. ; Zika virus) ' in. a subject, the method comprising the ste of administering to the subject a vaccine composition comprising; cells (i) comprising at least one flavivirus antigen (e.g., at least one Zika virus antigen), and (ii) expressing at least one cytokine.
  • a flaviyirus e.g. ; Zika virus
  • a vaccine composition comprising; cells (i) comprising at least one flavivirus antigen (e.g., at least one Zika virus antigen), and (ii) expressing at least one cytokine.
  • the present disclosure pro des a method of elic iting an immune response to a flavivirus (e.g., Zika virus) in a subject, the method comprising the step of administering to the subject a vaccine composition, comprising: a first population of cells comprising at least one flavivirus antige (e.g., at least one Zika vims antigen), and a second population of cells expressing at least one cytokine.
  • a flavivirus e.g., Zika virus
  • a vaccine composition comprising: a first population of cells comprising at least one flavivirus antige (e.g., at least one Zika vims antigen), and a second population of cells expressing at least one cytokine.
  • the present disclosure provides a method of preventi ng and/or treating flavivirus infection (e.g., Zika virus infection) in a subject, the method comprising the step f: (a) administering to the subject a first population of celts comprising at least -one flavivirus antigen (e.g., at least one Zika virus antigen), and (b) administering to the subject a second population Of cells expressing at least one cytokine.
  • flavivirus infection e.g., Zika virus infection
  • the present disclosure provides a method of eliciting an immune response to a flavivirus (e.g., Zika virus) in a subject, the method, comprising the step of: (a) administering to the subject a first population of cells comprising at least one -flavivirus antigen (e,g., at least one Zika virus antigen), and (b) administering to the subject a second population of cells expressing at least one cytokine.
  • a flavivirus e.g., Zika virus
  • the first population of ceils comprising at least one flavivirus antigen (e ⁇ g.,. at least one Zika virus antigen), and the second population of ceils expressing at least one cytokine may be co-administered to a subject.
  • the first population of cells comprising at least one flavivirus antigen e.g., at least one Zika virus antig n
  • the term "co-adrainistering” refers to a process where the first populatio of cells comprising at least one flavivirus antigen (e.g., at least one Zika virus antigen) and the second population of cells expressing at least one cytokine are encountered by the subject's immnn system at essentially the same time.
  • the two populations of cells may or may not be administered by the same vehic le, If they are administered in two separate vehicles., they can be administered sufficiently closely, b h 'in time and by route of administration, tha they ate ⁇ encountered, essentially siumltaneous!y by the s «bject% immune system to achieve the de ired specificity.
  • the present disclosure relates to compositions and methods of regulating the immune response of a subj ect to a virus antigen by administering a mixture' of the v ms antigen, and one or more cytokines, and/or adhesion or accessory molecules, in such a manner that the immune System of the subject is stimulated, in certain embodiments, the antigen, the cytokine, and/or the adhesion or accessory molecule, are coadministered ia a therapeutically effective amount, which results in the systemic immune response *
  • the present composition and method provide for transfer or release of the cytokine., and/or the adhesion or accessory molecule, in direct proximit or in combination with the virus antigen.
  • the cytokine and the vims antigen may be administered in the same vehicle, or may be administered in two separate vehicles. If they are administered In two separate vehicles, they are administered sufficiently closely , both in time and by route of administration, thai they are encountered essentially simultaneously by the individual's immune system.
  • the cytokine, andbr the adhesion or accessory molecules can be co-administered with the vims antigen in any manner which provides transfer or delivery of the cytokine in the context of the v irus antigen in relatio to which the Immune response is to be regulated. For example * this can be accomplished by rising slow or sustained release delivery systems, or direct injection.
  • the nonspecific cytokine has the specific effect of amplifying- or altering the specific iminnne response to the virus antigen. The emphasis is on local interaction of the cytokine and the virus antigen to mimic the physiological occurrence of simultaneous presentation of cytokine and antigen, to maximize efficacy and minimize toxicity.
  • a vaccine c an comprise an antigen, which is a virus or a component of die vims, or a fragment thereof, that is introduced into subject to be vaccinated in a non-toxic, non-infectious and/or non-pathogenic form
  • virus antigens include whole Mv « attenuate viruses (modified to reduce their virulence) or inactivated viruses, individual viral components (e.g, , protein or polysaccharides) and the genetic material of the virus (e.g, :1 RNA or DNA), The
  • disorder or condition e.g., afflicted by viral infection.
  • susceptible to or “prone to” or “predisposed to” a specific disease or condition e.g., viral infection
  • l ke refers to a subject who based on genetic
  • An increase in likelihood of bein infected by the virus may be an increase of about 10%., 20% , 50%, 100%, 150% , 200%, or more.
  • the terms "treat,” treating,” “treatment/ * and the like refer to reducing or ameliorating a disorder (e.g., viral infection) and/or symptoms associated therewith.
  • the term "effective amount'* refers to am amount of the compositio or cells that is sui cient to stimulate* enhance, or elicit ⁇ the mmune response of a subject against a flawwus (e.g,, Ztka. vk s).
  • an "immonological response” or “immune response” to an antigen, or vaccine or co sition comprising the antigen is the development its a .rna malian subject of a umoral • and/or a cellular immune response to the antigen.
  • An 'immunological response” or “immune response” as used herein encompasses at least one or more of the following effects; tire
  • a "cel lular immune response" is one mediated by T-lymphoeytes and/or other white blood cells, including without limitation H cells and macrophages.
  • Functionally cellular immunity includes antigen specific cytotoxic T cells (CTL).
  • CTL antigen specific T cells
  • Antigen specific T cells, CTL, or cytotoxic T cells as used herein refers to cell which have .specificity for peptide antigens presented in association with proteins encoded by the major histocompatibility comple (MHC) or human leukocyte antige s (HLA) as the proteins are referred to in humans.
  • MHC major histocompatibility comple
  • HLA human leukocyte antige s
  • CTLs of the present invention include activated C TL which have become triggered by specific antigen in the context of MHC; and memory CTL or recall CTL to refer to T cells that have become reactivated as a result of re-exposure to antigen as well as cross- reactive CTL.
  • CTLs of the present disclosure include CP4+ and D8+ T cells.
  • Activated antigen specific CTLs of the present disclosure promote the destruction, and or lysis of ceils of the subject infected with the pathogen or cancer cell to which the CTL are specific via amongst other things, secretion of chemokines and cytokines Including without limitation macrophage inflammatory protein I a ( IP-la), MIF- 1B S and RANTES; and secretion of soluble factors that su press the disease state, Cellular immunity of the present disclosure also refers to antige specific response produced by the T helper subset of T cells.
  • Helper T cells act to help stimulate the function, arid .focus the activity of nonspecific effector cells against cells displaying peptide in association with MHC molecules on their surface;
  • a cellular immune response also refers to the production of cytokines, chemokines and other such molecules produced by acti vated cells and/or other whit blood cells including those derived from CD4 and CDS T cells and NK cells,
  • a composition or vaccine that elicits a cellular Immane response ma serve to sensitive a mammalian subject ' by the presentation of antigen in association with MEC molecules at the cell surface.
  • the cell-mediated immune response is directed at, or near, cells presenting antigen at their surface.
  • antigen-specific T-lytaphoeytes can be generated to allow for the future protection of an immunized host
  • the ability of a particular antigen to stimulate a cell- mediated immunological response may be determined by a number of assays known i the art. Such as by lyiBphoprolifefation (lymphocyte ' ctivation) assays, CT ' L cytotoxic cell assays, or b assaying for T ymphoeytes specific for the antigen i a sensitised subject Such assays are -well known in the art. See, e,.g... Brlekson et a!., J.
  • Methods of measuring cell-mediated immune response include measurement of inftaeeliuiar cytokines Or cytokine secretion b T ⁇ cell populations, or by measurement of epitope specific T-ee ls e,g. t by the tetramer technique) (reviewed by
  • immune response encompasses one which stimulates the production of CTJLs, and/or the production o activation of helper T-cells and/or an antibody-mediated immune response.
  • the present method and composition may regulate the knraune response to a itaviviros (e.g. , Zika virus) in a subject.
  • a itaviviros e.g. , Zika virus
  • the term "regulating the immune response” refers to any alteration in any cell type involved i the immune response.
  • the definition is meant to include m increase or decrease in- the numbe of cells, an increase or decrease in the activity of the ceils, or any oilie changes which can occur within me immune system.
  • the cells may be, but are not limited to , T lymphocytes, B lymphocytes, natural killer (NK) cells, macrophages,, eosinophils, mast cells, dendritic cells, or neutrophils.
  • the definition encompasses both a stimulation or enhancement of the immune system to develop a sufficiently potent response to a deleterious target, as well as a suppression of the immune system to avoid a destructive response to a desirable target, in the case of stimulation of the immune system, the definition includes future protection against subsequent viral challenge.
  • Zika ' Virus and J3 ⁇ 4viylr uses The present compositions and methods can be nsed for the treatment and/or prevention, of infection caused by a ffevivirus *
  • the Flav virus family (Flavivjridae) are single-stranded ⁇ + ⁇ RNA v ras.
  • flavivirases - include arthropod-transmitted human pathogens.
  • Nan-limiting examples of ftaviviruses include Zika vims, the dengue virus (DENY), the yellow fever virus (YFV), the West Nile virus (WNV), the Japanese encephalitis virus (JEV), the St. Louis encephalitis virus, and the tick-borne encephalitis virus.
  • compositions and methods can be used for the treatment and/or prevent on of infection caused by Zika. vims, inc luding any strain of Zika vims.
  • ZlK r is a ..member of the Spondweni. group; both genetically and serologically.
  • cells used for the generation of the vacc ne composi tion are infec ted with two or more strains of Zika viruses, in certain
  • cells infected with distinct strains of Zifca viruses are combined and ' formulated into one vaccine composition.
  • a virus antigen may refer to any protein., carbohydrate, nucleic acid (RNA or DMA), or other component capable of eliciti ng an immune response.
  • a virus antigen e.g., a Zika virus antigen
  • the virus antigen comprises the Savivinxs (or Zika virus) E-glyeeprotein or fia.vivin.5S envelope glycoprotein, eapsid protein, nucleocapsid, and/or a viral glycoprotein.
  • the virus antigen e f g, s a Zika virus antigen
  • the Zika virus antigen comprises at least one nonstmclural protein m w-- at least one structural protein of the vims (e.g harass Zika vims).
  • the Zika virus antigen comprises at least one nonstractural protein and/or at least one structural protein of the virus (e.g.; Zika virus).
  • the present cell may contain at least one virus antigen (e.g., at least one flavi virus
  • the present eel! may contain I, 2, 3, ., 5, ,6, 7, 8, 9. 10 or more virus antigens (e.g., fiavivirus antigens, or Zika vims antigens).
  • virus antigens e.g., fiavivirus antigens, or Zika vims antigens.
  • Non-limiting examples of the virus antigens include the envelope (E) protein, the membrane (M) protein, viral RMA, a eaps d (C) protein, a structural, protein., a membrane precursor (Pr ) protein, a part or complete envelope, a nonstructural protein (e g., MSI* NS2A, S2B, NS3, N.S4A, NS4B, and ⁇ $5) of the vims (e.g., tlavivirus, or Zika vims).
  • a nonstructural protein e g., MSI* NS2A, S2B, NS3, N.S4A, NS4B, and ⁇ $5
  • the vims e.g., tlavivirus, or Zika vims.
  • Bo!lati et ai Structure and functionality in t aviviros S-proteins: Perspectives for drug design, Antiviral Research, 2010, 87(2);.! 25-148.
  • the vims antigen is a viral peptide, polypeptide or protein *
  • the antigens of a f!avivirus e.g., Zika vi s
  • Zika vi s are at least one inactivated or attenuated whole virus
  • An antigen refers to a molecule containing one Or more epitopes (either linear,
  • An antigen may be a virus (e.g:, an inactivated vims, : or an attenuated virus), a whole protein, a truncated protein, a fragment of a protein or a peptide.
  • Antigens ma he naturally occurring, genetically engineered variants of the protein, or may be eoclon optimized for expression in a particular mammalian subject or host.
  • -a B-cell epitope will include at least about 5 amino acids but can e as small as 3-4 amino acids
  • a T-cell epitope, such .as a G L epitope will include at least about 7-9 amino acids, and a helper 1 -ceil epitope at least about 12-20 amino acids.
  • an epitope will include between about 7 and 15 amino acids, such as, 9, 10, 12 or 15 amino acids.
  • the term ' "antigen* denotes both snhutiit antigens, (i.e., antigens which are separate and discrete from whole organism: with which the antigen is associated in. nature). Antibodies such -as.
  • anti-idiotype antibodies or fragments thereof, and synthetic peptide mlmotopes., that is synthetic peptides which can mimic an antigen or antigenic ' determinant, are also captured under the definition of antigen as used herein *
  • an "antigen" refers to a protein, which includes
  • Immunological response as defined herein. These modifications ma be deliberate, as through site-directed mutagenesis, or may be accidental, such as through mutations of hosts which produce the antigens. Antigens of " the present disclosure may also be codon o imized by methods known in the art to improve their expression or irmhunogenicity in the host.
  • a "cross reaction" immunogenic determinant refers to a determinant, epitope, or antigen which is capable of eliciting an immune response to related but not identical antigenic determinants.
  • Viruses may be inactivated by irradiation, a physical method, a chemical method, or a combination thereof
  • Viruses e.g., Zika vims
  • gamma irradiation ultraviolet irradiation
  • heat heat, or other methods know in the art.
  • Viruses may be inactivated using physical and/or chemical method.
  • a range of inactivafion agents or methods have been described to inactivate viruses for vaccine purposes.
  • Examples of viral inactivation methods include, gamma irradiation (Martin et al.
  • a virus e,g., ZiiSV
  • gamma irradiation e.g., ZiiSV
  • the suitable irradiation dose to inactivate a virus in cells may vary upon the virus, speci fic iral strain, nuhiher of cells carrying a virus, etc.
  • the gamma irradiation dose for inaciivaiiori of the virus ranges from about 20 kGy to about 40 k ⁇ 3y, from about 25 kGy to about 40 kGy, from aboat 25 kGy to about 35 kGy, from about 20 kGy to about 35 kGy, or from about 25 kGy to about 30 kGy.
  • a virus e.g., ZIKV cm be inactivated using UV irradiation.
  • UV with a wavelength ranging fforn about 230 mm to about 280 nro e.g., at energies 900-1000 joule/m
  • UV with a wavelength of about 254 nra is used for the inaeiivatio of a vims (e,g>, ZIKV).
  • a virus e.g., ZIKV
  • ZIKV Zika virus
  • a virus is Inactivated by beat treatment at a temperature ranging from about 45"C to about 80" €1 froni about 45"C to about 7$°C, f orn about 50*C to about 75 f, C, from about 5 fC to about 70%, or from about 5 ( f to about 603 ⁇ 4,
  • virus e.g. , ZIK i inactivated by irradiation or heat treatment for about 10 minutes to about 5 hours, about 20 minutes to about 3 hours, about 20 minutes to about 2 hours, about 30 minutes to about 1 hour, or longer.
  • the regimen used for inaeiivation of Zlka virus in infected cells also renders die ceils proliferation incompeten
  • the virus e.g., Zlka virus
  • a chemical agent such as fottnahn (formaldehyde), beta-propiolae ne (i3 ⁇ 4Fl ), hydrogen: peroxide, lutataldehydej -aeety!etfryieneimine, binary ethyieneinnns, tertiary eihyleneiniine, ascorbic acid, capryiie acid, psolarens, detergents including non-ionic- detergents etc.
  • a chemical agent such as fottnahn (formaldehyde), beta-propiolae ne (i3 ⁇ 4Fl ), hydrogen: peroxide, lutataldehydej -aeety!etfryieneimine, binary ethyieneinnns, tertiary eihyleneiniine, ascorbic acid, capryiie acid, psolarens, detergents including non
  • MAC-ELIS A enzyme- linked immunosorbent assay
  • the present, cells comprise human cancer cells that are genetically modified to secrete GM-CSE.
  • the present cells are pancreatic cancer cells, colon cancer ceils, lung cancer cells, breast cancer cells, ovarian cancer cells, prostate cancer ceils, melanoma ceils, or combinations thereof.
  • the present vaccine composition comprises allogeneic pancreatic ductal adenocarcinoma (PDA) tomor cells engineered to secrete GM-CSF.
  • PDA pancreatic ductal adenocarcinoma
  • the vaccine comprises: GM-CSF-seereting PDA vaccine (G ⁇ AX),
  • the ceils are permissive to infection by ZiKV.
  • vaccine compositions and methods ' of the present disclosiire can employ an cell type whic is pemiissiv for ZIKV infection, where the ceils are maintained in a surviving mode immediately upon infection with Zika viras (i.e., cells are not killed by the virus immediately follo wing the infection).
  • the ability of the cells to secrete GM-CSF- f cilitate the ability of the cells to secrete GM-CSF- f cilitates the
  • the present ceils comprise skin immune cells, including dermal fibroblasts, epidermal kera&nocytes, and immature dendritic ceils (X Virol. 2015 Sep 1 ; 89(17): 8880-8896). in certain em odiment the present cells comprise epithelial cells. In certain embodiments, the present ceils comprise- nenroprogeniiot cells, MlaJkar et al. 5 N. Emi). J Med. 374951-958. (2016); Sarao ei al. PloS Hegl. Trop. Pis. 10 (2016); Tang et al. Cell Stem Cell. 18(5):-587-90 (2016),
  • the present cells are Vero cells, N2a cells, human fibroblast WS- 1 cells, human fibroblast PCS201--G12 cells, RC-5 -cells. WI-38 ee3 ⁇ 4 BH -21 cells, CBO cells, C6 C3, or combinations thereof.
  • At least one vims antigen may be introduced into, or loaded onto, the present cells.
  • nucleic acids encoding at least one viras antigen e,g t , Zika viras antigen
  • the cells may be antigen -presenting cells (APCs).
  • APCs antigen -presenting cells
  • Non-limiting examples of antigen-presenting cells including dendritic cells, macrophages., B cells, cells of myeloid lineage, Langerhans ceils, epithelial cells, or any nucleated cells.
  • the APC may be autologous or allogeneic;
  • the AFC may be isolated from a subject
  • the APC may also be derived from cells isolated from a -subject.
  • DCs Dendritic Cells
  • innnaiirre precarsors e.g., • monocytes
  • CD34+ cells i.e., cells expressing €034
  • the cell ma -co-express human leucocyte antige (HLA).
  • HLA human leucocyte antige
  • The: HI, A expression by the cell may be the result of a . atural process or due to recombinant expression ofHLA,
  • the HLA. expression may be as a result of HLA expression, by the cell by endogenous processes, Alternatively, the HLA expression ma occur as a result of recombinant engineering and protein production.
  • Cells may be contacted with nucleic acids encoding on or more vims ntigeos (e.g. i Zlka virus antigens), for example, cells can be transfected with expression vectors or infected with viral vectors for i troducing .nucleic, acids encoding one or .more virus niigeiis (e.,g. , Zika virus antigens) inio the cells.
  • vims ntigeos e.g. i Zlka virus antigens
  • nucleic acids into ceils include* but are not limited to, eiec ' ttoporatkm, jmkroinjection, ' hypotonic shock, scrape loading, catioriic liposomes, and calciu phosphate eopreeipitation *
  • the time a id amount of antigens, or nucleic acids encoding the antigens,, necessar for the antigen presenting cells to process and present the antigens can be determined, for example, by assaying T cell cytotoxic activity in vitro or using antigerj-presentirsg eels as targets of CTLs, Other methods that can detect the presence of antigen on the surface of antigen-presenting cells are also contemplated by the presented invention.
  • the antigen-presenting ceds loaded with the antigen can be used to stimulate CTL proliferation In vivo or ex ⁇ ,
  • the ability of the loaded dendritic cells to stimulate a CTL response can be measured by assaying the ability of the effector cells to lyse target ceils.
  • the non-radioactive LDH cytotoxicity assay or the europium release assa can be used, Volgmarin et at* J. Immunol. Methods 119:45-51 , 1.989.
  • Expression can be optionally eifeeted by targeting -the. expression construct to specific cells, such as with viral vector or a receptor ligand, or by using a tissue-specific promoter, or combinations thereof,
  • the present cells are loaded with one or more virus antigens (e.g., Zika virus antigens).
  • virus antigens e.g., Zika virus antigens
  • a cell "loaded” (or “pulsed") with peptide shall mean that the cell has been incubated with the peptide under conditions pennitting entry into, and/or attachment onto, the cell of the peptide.
  • APCs e.g., dendritic cells
  • virus antigens e.g., Ska virus antigens
  • Suitable conditions for antigen loading are provided that, permit an APC to contact, process and/or present one or more antigens
  • the cells of interest i e,, mature DCs
  • the cells of interest can be purified prior to administration to the subject.
  • .Purification of the cells can. be done usin a variety of methods n wn in the art, including methods in which antibodies to specific ceil surface molecules are employed, Ibese methods include both positi ve an negative selection methods.
  • Ibese methods include both positi ve an negative selection methods.
  • cells generated in vitro cm be isolated by staining the cells with fhioreseently labeled antibodies to cell surface markers followed by sorting of the cells that express both of these markets on their cell surface using fluorescence .activated cell, sorting (FACS). These and other purification/isolation methods are well known to those of skill in the art.
  • he present cells may be inactivated or rendered proliferation incompetent by any suitable technique kn wn- in the ar such, as gamma irradiation of UV irradiation.
  • Proliferation incompetent cells are ceils that have been treated in such a way that renders them unable to underg mitosis, .bat still maintain the capacity to express proteins, such as a cytokine (e.g., GM ⁇ CSF), '
  • f r cells infected with ZI V, cells can be treated to .inactivate the vires and rendered proliferation incompetent.
  • the cells are rendered proliferation incompetent using gamma irradiation.
  • gamma irradiation dose to inactivate/growth arrest a cell or population of cells may vary upon the cell type and/or number of cells.
  • the gamma irradiation dose for rendering cells proliferation incompetent ranges fro about 100 Gy (Gray) to about 300 Gy.
  • th gamma irradiation dose for rendering cells proliferation incompetent ranges front about 150 to about 30 Gy.
  • cells are rendered proiifeiation. incompetent using OV irradiation.
  • cells comprising inactivated iilavivituses (e,g. , Zika virus)
  • cells are first infected with flavivirases (e.g., Zika viruses).
  • flavivirases e.g., Zika viruses
  • tlayivlruses e * g ⁇ , Zika viruses
  • tlayivlruses can be inactivated in such, cells to prevent propagation of th viruses upon administration to a subject.
  • the gamma irradiation levels for rendering the cells proliferation incompetent are approximately two orders of magnitude lower than those required for virus inacti vation. Thns, irradiating cells at the levels required for the virus inactivation may
  • ells expressiug GM ⁇ CSF may be used as bystanders 1 ⁇ 2 combination with virus-loaded cells>
  • This rmmyBtsai on scenario can be accom lished by initially dividing ceils into two fractions: (i) cells infected with flaviviruses (e.g. . , Zika viruses); and (ii) cells not infected with favivifuses (e.g., Ska viruses). Then only fraction (i) of the cells (but not fraction ⁇ 3 ⁇ 4)) will, be treated to inactivate the viruses.
  • flaviviruses e.g. . , Zika viruses
  • favivifuses e.g., Ska viruses
  • fraction (ii) will not need to be exposed to high radiation levels, as it lacks viruses. Sock approach ensures that cells that flaviviruses (e.g *> Zika viruses) are irradiated at the levels required, for tendering the cells proliferation Incompetent, which allows them to maintain the ability to express GM-CSF.
  • the two fractions of cells are then combined and administered to a subject.
  • the present composition may express or comprise at least one cytokine:.
  • Cytokines include the general class of hormones of the cells of the imnume system, including !ymphokmes, monokines, and others.
  • the present composition may express o comprise an imm.unomodulating cytokine, which Is any cytokine that is involved in immune system regulation or has an effect ⁇ upon modulating the immune response.
  • Cytokines suitable for use in the present vaccine compositions include, but are not limited to, GM-CSF, m interleukin, an interferon, and tumor necrosis factor.
  • cytokines include interferon alpha (lFN- ⁇ ), inter ei&ift ⁇ ⁇ (iL ⁇ 2J * inter leak g (IL ⁇ 4), interleukin- 2 (IL* 12), TNF -alpha, and granulocyte niacro hage-colony stimulating factor (GM- CSF), r combinations thereof.
  • Non-limiting examples of cytok nes include, GM-CSF, IL-l (IL- ialpha or IL-ibeta), lL-2, 1L-3, IL-4, IL-5, IL-6.
  • the cytoki ne is substantially similar to the human form of th protein, oris derived from the protein of the human sequence (i.e.:, of huma origin),
  • cytokines of oilier m3 ⁇ 4mmak with substantia! homology to the human forms of.IL- ⁇ 2, GM-CSF,, TNF ⁇ aIp a, and others may e used in. me present composition or method when demonstrated to exhibit similar activity on the immune system.
  • the present composition or method uses proteins that are substantially analogous t any particular cytokine, but have relatively minor changes -of protein sequence,
  • immunomodulatory cytokines such as GM-CSF can he used as- adjuvants to whole-ceil based vaccine to enhance the vaccine efficacy.
  • the GM-CSF may he Mi-length human GM-CSF, or may have an amino acid sequence 80%, 85%, 90%, or 95% identical to a &II lengt human GM-CSF, which has one ot more biological activities of lull length GM-CSF. Examples of biological activities of GM-CSF include its capacity to stimulate macrophage differentiation and proliferation, or ac tivation of antigen presenting dendritic cells .
  • the GM-CSF sequenc may include one or more mutations which can be amino acid substitutions, deletions, o additions.
  • Methods for the evaluation and the measurement of the biological activity of GM-CSF proteins are known n the aft. U.S. Patent No, 7,371,370,
  • cytokines, antigens, or hormones of other mammals with substantial homology to the human forms of the cytokines, antigens, and hormo eSj will be useful in the invention when demonstrated to exhibit -similar activity on the immune system.
  • compositions of the present disclosure can be any suitable cytokines, ' vaccin compositions of the present disclosure.
  • the virus antigeu($) ma be i trodu ed into t e cell, or loaded onto the celt using any vector.
  • the cell may be genetically engineered using an vector to express cytokine.
  • the term " vector” refers to a polynucleotide capable of transporting another nucleic acid to which it has been linked.
  • the present vectors can ' be, for example, a plasrrud vector* a single- or dotjfete-strande phage vector, or a single- or double-stranded RNA or DNA viral vector.
  • Such vectors inrissa, but are not Mtriited to, chromosomal, episomal and vims-derived vectors, e.g., vectors derived from bacterial plasrnids, bacteriophages, yeast episonies, yeast chrornosornal elements, and viruses S ch as baouiovituses, papova viruses, SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, and vectors derived fto combinations thereof, such as those derived .from, plasrnid and bacteriophage genetic elements, cosmids and phagemids.
  • vectors derived from bacterial plasrnids, bacteriophages, yeast episonies, yeast chrornosornal elements, and viruses S ch as baouiovituses, papova viruses, SV40, vaccinia viruses, adenoviruses, fowl po
  • Expression vectors can be Used to replicate and/of express the nucleotide sequence encoding, e.g., a vims antigen, and/or a cytokine in a cell (e.g., a mammalian ceil such as ' hitman cell).
  • a variety of expression vectors useful for introducing into cells the polynucleotides of the in ventions are well known in the art
  • Recombinant vectors are prepared usin standard techniques known in the art, and contain suitable control elements operably linked to the nucleotide -sequence encoding the target antigen. See, for example, Plotkin, et al (eds,) (2003) Vaccines, 4 ed,, W.B. Saunders, Co., Pfrifa,, Pa.; Sikora, et al. (eds.) (1996) Tumor Jrnmunology Cambridge University Press, Cambridge.
  • Non-limiting viral vectors include retroviral vectors, adenoviral vectors, adeno-associated viral vectors, lentiviral vectors, siadbis viral vectors, lierpesviral vectors, SV-40 vectors, and pox viral vectors, siicb as vaccinia viral vectors, bacu!oviral vectors, alphaviraS vectors.
  • the vector is an adeno-assoeiated vims (AAV, or adenovirus- assoeiat d virus) vector.
  • AAV adeno-assoeiated vims
  • Any of the AAV. serotypes may be used, including, but: not limited to,. AA VI, AAV2, AAV3, AAV4, AAV5, AAV6, AAV?, AAVS, AAV9, AA IO,
  • Adenoviruses are described in, e,g.., Kosenfeld et al, 1991 ? Science 252:431-434;
  • the present expression vector is a lentivirtts (inekid ng ht aan immtmpdeficieacy virus (HIV)), which is a sub-type of retrovirus.
  • HIV immtmpdeficieacy virus
  • Plasniids thai may fee used as the present expression vector include, but are not limited to, pcDHA3.1, peONAS. i-hygro, pGL3, pCDMS (Seed, 1987, "An LFA-3 cDNA encodes a phospholipid-liuked membrane protein homologous to its receptor CD2", Nature * 840-842) and pMT2PC ⁇ Kaufman et al, 1987, ' “Translations! efficiency of polycistronic mRNAs and their utilization to express heterologous genes in mammalian cells", FMBO J. 6; 187-193). Any suitable plasmid ma he used in the present in vention.
  • Bacterial vectors include, for example, .Salmonella * Shigella, Yersinia, Lactobacillus,. Streptococcus, Baeil!s Calraeae-Guena,. Bacillus ' anthraeis, and Escherichia coii.
  • the bacterium can be engineered to contain a -nuclejc-acid-eiicodirig- reco binant -antigen.,: a heterologous antigen, or an antigen derived from a tumor, cancer cell, or infecti ve agent Moreover, the bacterium ca be modified to he afte t ⁇ e&ih anotae* aspect, -fne- n0n4
  • vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., episomal mmmaialian vectors).
  • Other vectors e.g., non-episotiaal mammalian vectors
  • a .host cel l upon introduction into the host cell, and thereby are repli cated along with the host genome.
  • a vector comprising nucleic acid sec ence encoding a cytokine (and/or a nucleic acid sequence encoding a virus antigen) may be ti&nsferred to a ceil in vitro, using any of a number of methods known in the art, which include electtoporation, membrane fusion with liposomes,. Lipofectamine treatment, incubation with calcium phosphaie-DNA precipitate, DEAE-dextran mediated transfection, infection with modified viral nucleic acids, direct microinjection into single ceils, etc.
  • vaccine coniposiiions aud rneihods of the present disclosure can be used to prevent and/or treat symptoms and adverse outcomes associated with flavivirus infection (e,g., ZJKV infection).
  • flavivirus infection e.g., ZJKV infection
  • vaccine compositions and methods of the present disclosure can be used for the prevention of microcephal and other brai anomalies associated with Zika .infection in newborns.
  • vaccine compositions and methods of the present disclosure can be used to prevent negative outcomes associated with Zika infection in adults, such as increased risk of Guillain-Barre syndrome.
  • the present composi tion ma ' be adnrinisiered to a sub ject t prevent or trea t viral infection, and/or th symptoms: associated therewith.
  • the present composition may be administered to a subject prior to infection, by the virus (e.g., Zika virus).
  • the virus e.g., Zika virus.
  • cells expressing GM-CSF and cells comprising inactivated inactivated t1 ⁇ 2ytv.iruses are rendered proliferation incompetent and formulated int two separate vaccine eon*positions.
  • vaccine compositions can be adiBtofstered simisltaneonsiy, separately or sequentially.
  • the present composition comprises GVAX comprising at least one vims antigen (e.g., Zika vires antigen).
  • vims antigen e.g., Zika vires antigen
  • 0 VAX may refer to an. inactivated tumor cell.
  • GM- CSF granulocyte maerephage-eolony stimulation factor
  • AH I is an epitope of gp70, an tnunmiGdomtnartt antigen of C 26 cells.
  • compositions described herein may be used for the prevention and/or treatment of fiavivims infection (e.g., Zika virus infection) in a subject, either ' alone or in combination with other methods suitable tor the preventio and or treatment of ftavivirus infection (e.g., Zika virus infection).
  • fiavivims infection e.g., Zika virus infection
  • ftavivirus infection e.g., Zika virus infection
  • Dosages may be titrated to optimize safety and efficacy.
  • dosage-effect relationships from, in vitro studies can. provide useful guidance on the proper doses for patient administration.
  • Studies in animal models can also be used for guidance regarding effective dosages for treatment of flavivirus infection (e.g., Zika virus infection) in accordance with the present disclosure.
  • one or more than one administration of (he present composition s can be delivered to the subject in a course of treatment
  • multiple administrations - may be given at a single time point with the treatment repeated at various time intervals.
  • an in itial or pr iming (or prime) treatment may be followed by one or more booster (or boost) treatments.
  • the primin (or prime) and booster (or boost) treatments are delivered by the same route of administration and/or Any appropriate route of administration may be employed, for example, administration may be topical, arenteral intravenous, rotraarterial s subcutaneous, tratumoral iniramaseui&r, intracranial, ntraorbital, oplit hnie, intraventrkanar.. intrahepatic, intracapsular, intrathecal, intracistetnai, intraperitoneal, intranasal, aerosol, suppository, or oral administration.
  • therapeutic formulations may be in the form of liquid solutions, or sus nsions; for oral administration, formulations may be in the form of tablets or capsules; and for intranasal formulations, in the form of powders., nasal drops, or aerosols.
  • the administration of the present cells o composition (vaccination) may he given once, twice, three times, foilr times, five to s, six times, seven times, eight times, nine times, ten times, eleven times, twelve times, thirteen times, fourteen rimes, fifteen times, or more, within a treatment regime to a subject/patient
  • the admmtsiration of the present ceils or composition (vaccination) may be given every 2 days, every 3 days, every 4 days, every 5 days, every 6 days, every 7 days, every S: days, every 9 days, every _0 days, every 1 1 days, every 12 days, every 13 days, every 1 days, every 16 days, ever 18 days, every 20 days, every i month, every 2 mouths, every 3 months, every 6 months, or at different frequencies.
  • the present cells may be administered to a subject (e,g. s a huma -subject) at a dose ranging from about 1 X Iff* cells to about 1 X lQ n cells, from about I X 4 cells to about 1 X 10 K * cells, from about I X 10 " cells to about I X 1.0 s cells, from about I X 1.0* cells to about 1 X 0 s cells, from about: 1 X 10 6 cells to about 1 X 10 ' cells., from about 1 X 10 7 cells to about 1 X J ⁇ * cells, about 1 X 10 5 cells, about 1 X 1 * cells, about 1 X i0 7 cells * about f 10 8 cells, or about I X 10 ?> ceils.
  • the present cells are administered at a concentration of about 1.0 * cells/ml to about I0 ' cells/ml, about JO 3 cells/ml, about Iff cells/ml, about ⁇ 0 5 ceils ml, about lO 6 cells/ml, about 10 7 cells/ml, about 10 cells/ml, about l f cells/ml, about 10 i0 cells/ml, or about l ⁇ 1 eelis l.
  • the total volume of the present composition adm nostired is about 0.001 mL-about 10 raL, e.g., 0.01 niL, 0.1 niL, or 1 mh. In one
  • the present composition is administered at a concentration of about 2 X 10' cells/ml in total vol ame of about 0.1 mh.
  • the present composition is administered subentaseousiy.
  • toe vaccine Is ateiaisteted t ke or more, earrag., 3 times, 4 times, 5 times, 6 times, 7 times, 8 tiroes, 9 times, 10 times, 15 times., 20 times, 25 times* 30 times, 35 times, 40 titties, 50 times, 60 titties, 70 times, 80 times, 90 times or more, for example, the vaccine is administered at least once per week, e.g., at least twice per week, at least three times per week, at least fou times per week, at least five times per week, at least six times per week, at least seven times per week.
  • the vaccine is administered at least once per day, e.g., at least twice per day, at least every eight hours* at least every four hours, at least every two hours, or- at leas every hoar, in certain embodiments, the present compositions are administered for a duration of 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 2 weeks * 3 weeks, 4 weeks, five weeks, si weeks, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 moeths, 11 months, 12 months, 2 years, 3 years, 4 years, 5 years or more. In certain embodiments, the present composition is administered one dose every two weeks for 4 to weeks or until the viral infection is treated.
  • the present invention provides a method for eliciting in a subject an immune response to at least one vires antigen.
  • the method comprises administering to the subject cells comprising at least one virus antigen (or loaded with -at least one virus antigen),, or cells comprising nucleic acids encoding at least one vims antigen.
  • the cells may also express at least one cytokine.
  • the present ceils or composition when administered to the subject, may elicit a im uoe response to the vims (e.g., Zifca virus), and/or ma elicit an immune response to at least one virus antigen.
  • the present invention provides a method of preventing: and/or treating iral .m!eetiot!, the met od comprising administering to a SBbject a therapeutically or prophySacticall effective amount of a pharmaceutical composition (e.g., an immunogenic composition, or a vaccine composition), wherein the composition comprises: ceils (i) comprising at least one flavivirus antigen (e.g., at least one Zika virus antigen), and (ii) expressing at least one cytokine.
  • a pharmaceutical composition e.g., an immunogenic composition, or a vaccine composition
  • the composition comprises: ceils (i) comprising at least one flavivirus antigen (e.g., at least one Zika virus antigen), and (ii) expressing at least one cytokine.
  • the present in vention provides a method of preventing and/or treating viral infection, the method comprising administering to a subject a therapenticaily o prophylaeticslly effective amount of a pharmaceutical composition (e.g., an immunogenic composition, or a vaccine composition), wherein the composition comprises; a first population of cells comprisin at least one fiavivirus antige (e.g, , at least one Zifca virus antigen), and second population of cells expressing at least one ey3 ⁇ 4Mne, sncb as G -CSF.
  • a pharmaceutical composition e.g., an immunogenic composition, or a vaccine composition
  • the composition comprises; a first population of cells comprisin at least one fiavivirus antige (e.g, , at least one Zifca virus antigen), and second population of cells expressing at least one ey3 ⁇ 4Mne, sncb as G -CSF.
  • die present cells antige -present3 ⁇ 4g cells
  • die present cells antige comprising one or more virus antigens (or a fragment thereof) may be used to contact lymphocytes under conditions sufficient to produce virus aaiigen-specific lymphocyte capable of eliciting an:
  • the antigen-presenting cells also can be osed to provide lymphocytes, including T lymphocytes and B lymphocytes, for eliciting a immune response against a cell that comprises a vires antigen.
  • a preparation of T lymphocytes is contacted with the antigen-presenting cells described above for a period of time, tor priming the T lymphocytes to the at least one vims antige presented by the antigen-presenting cells.
  • T lymphocytes and B lymphocytes thai are primed to respond to cell s that comprise a virus antigen can be prepared,
  • T lymphocytes can be obtained from any suitable source such as peripheral blood, spleen, and lymph nodes.
  • the T lymphocytes can be used as crude preparations or as partially purified or substantially purified preparations, which can be obtained, by standard techniques including, bnt not limited to, methods involving immimomagnetic or Sow cytometry techniques using antibodies.
  • T cells can be removed from a subject and treated in vitro with the present cells (e.g. * , antigen-presenting cells), wherein the resulting CXL are reiofused autologous ly or aflogeneically to the subject,
  • present cells e.g. * , antigen-presenting cells
  • the antigen-prirned antigen-presenting cells of the preserti disclosure and tire antigen-specific T lymphocytes generated with these antigen-preseming ceils c n: fee used as Imniunomodulating composition for prophylactic or therapeutic applications for viral infection.
  • the virus antigen-primed atrtigen-presenting cells of the present disclosure can be used for generating CD8+ CTL, €D4+ C3 ⁇ 4 and/or B lymphocytes for adoptive transfer to the subject,
  • virus antigen-specific CTLs can be adoptively transferred for therapeutic purposes in subjects afflicted with viral infection.
  • the present compositions- r meth ds may function t provide or enhance an Immune response.
  • the immune response can include humoral immune response, -cell-mediated i mun response, or both.
  • antigen presentation through an. »3 ⁇ 4m «aologica-l pathway involving MH.C class O molecules or direct B ⁇ eeil sti ulatio can produce a humoral response; and, antigens presented through a pathway Involving M C 1 molecules can elicit cell-mediated immune response
  • a humoral response can be d ' eteranned b a standard immunoassay fo antibody levels in a semm sample from the subject receiving the pharmaceutical composition, A ⁇ cellular immune response is.
  • a response thai Involves T cells and -can b determined in vitro or in vi vo,
  • a general cellular immune response can be determined as the T cell proliferative activity ' in cells (e.g., peripheral blood leukocytes (PB:Ls)) sampled from the subject at a suitable time following the administering of a harma eutical composition.
  • PB:Ls peripheral blood leukocytes
  • T cell cytotoxicity can also be determined.
  • compositions- and/or methods will, generally at least in part be immune-mediated, although, an immune response need not be positively demonstrated in order for the composi tions and methods described herein to fall within th e scope of the present disclosure.
  • While one round of vaccination may be sufficient to generate sustained and protective immu e response* periodic booster (or boost) treatments ma be administered.
  • booster (or boost) treatments are administered 6-12. months following the initial vaccine administration, or following previous booster (or boost) administration.
  • An effective ainounf of a prime or boost vaccine may be .given in one dose, but is not restricted to one dose.
  • the administration can be two, three, four,, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or more, administrations of the vaccine.
  • the administrations can be spaced by time intervals- of one minute* two minutes, three, four, fi e, six, seven, eight, nine, ten, or more minutes, by intervals of about one hour, two hours, three, tour, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, IS, 19, 20, 21, 22, 23, 2 hours, and so on.
  • the adn'sinistratioBS can also be spaced by time intervals f one day , two days, three days, four days, five days, six days, seven days, eight days, nine days, ten days, 11 days, 12 days, 13 days, 14 days, 15 days, .16 days, .1.7 days, 18 days, 19 days, 20 days, 21 days, and combinations ⁇ thereof.
  • the invention is .net limi ted to dosing intervals that are spaced qually in time, but encompass doses at non-equal intervals* such as a priming schedule consisting of administration at 1 day, 4 days, 7 days, and 25 days, just to provide a non-limiting example.
  • the following may be take into consideration in determioiug the relative timing of the prime vaccine and boost vaccine. It has been found that dminis ration of an antigen, or nucleic acid encoding an antigen, can stimulate expansion of antigen-specific immune cells, resulting in a peak, followed b contraction of the number of antigen specific immune cells (see, e.g., BadOvinac , et al. (2002) Nature ' Immunol, 3 :61.9-626). Initiation of the boost vaccination Can be administered before the peak is reached, coincident wit the peak, or after the peak.
  • Admi stration of the boost vaccinati n can be initiated when a population of antigen- specific immune ceils has expanded (increased in ⁇ number) to at least 20% the maxima! number of antigen-specific immune ceils that is eventually attained; to at least 30%; to at least 40%; to a t least 50%; to at least 60%; to at least.70%; to at least 80%; to at least 90%; to at least 95%; to at least 99% the maximal number of antigen-specific immune ceils that is eventually attained.
  • the boost vaccination can fee initiated w hen the population of antigen-specific cel ls has contracte to under 90% t he maximal number of antigen-specific cells; under 80%; under 70%; under 60%; under 50%; under 40%; under 30%; under 20%; under 10%; under 5%; under 1.0%; under 0.5%; under 0.1%; under 0,05%; or under 0.01% the maximal number of antigen-specific immune ceils.
  • the antigen-specific cells can be identified as specific for a vector-specific antigen (specific for empty vector), otsp cifie lor a heterologous antigen expressed by a nucleic acid contained in. the vector.
  • administration of the boost vaccination can be initiated a t -about day s after the prime vaccination is initiated; about 10 days after the prime vaccinatio is initiated; about 15 days; about 20 days; about 25 days; about 36 days; about 35 days; about 40 days; about 45 days; about 50 days; about 55 days; about 60 days; about 65 days; about 70 days; about 75 days; about 80 days, about 6 months, and ab ut 1 year after administration of the prime vaccination is initiated.
  • the boost vaccination can be administered 5- 10 days after the prime vaccination; 10-15 days after the prime vaccination; 15-20 days after the prime vaccination; 20-25 days after the prime vaccmation; 25-30 days after me prime vaccination; 30-40 days after the prime- vaccination; 40-50 ' days alter the prime vaccination; 50-66 days after the prime vaccination; 60- 70 days after the prime vaccination; and so on.
  • the boost dose will enhance the prime dose imrnnne response by at least two-fold, at times between about three- aad five-fold or five-fold to ten- fold, or from ten-fold to I DO-feld or greater, in some eiiibodiroen ts of the inventi on the prime dos and boost dose wilt ave a synergistic effect on tire immune response, in some
  • the enhanced im une response will include a T-cel!: response.
  • the T-cell response will be a CDS ⁇ T-cell response
  • the prime dose and boost dose will break the mammal's tolerogenic state towards the target antigen *
  • Treating a subject using the present compositions and methods may refer to reducing the symptoms of the disease, reducing the occurrence of the disease, reducing . the severity of the disease, and/or preventing a disease from occurring.
  • to treat a subject means both preventing disease occurrence (prophylactic treatment) and treating a subject thai has a disease (therapeutic treatment).
  • treating a subject is accomplished providing or enhancing an iiniBune response in the subject.
  • the present, cell may comprise one or more virus antigens, including 2, 3, 4, 5 * 6, 7, 8, % 10 or more antigens.
  • the present cell comprises one or more inactivated (or attenuated) viruses (e,.g., one or more inactivated (or attenuated) Zika viruses). Additionally, multiple, independently generated cells can be administered to a. subject.
  • the present cells may be autologous, allogenic (e.g. , from a different donor subject thai is MHC matched or mismatched with the recipient subject) or heterologous to the recipient subject.
  • the cells can be introduced into a snbject. by any mode that elicits the desired trnmone response to the virus (e.g.;. Zifes virus).
  • Vaccine compositions of the present disclosure can be administered, for example, intramuscularly, intradera ally, subdem aHy, subcuianeously, orally, intraperitonea!iy,
  • compositions comprising a composition of the invention cat ⁇ be added to a physiological fluid, such as blood. Inhaled therapy is also provided,
  • the. quantity of the vaccine compositions described in the present disclosure for effective therap will depend upon, a variety of factors ⁇ including the type of strain of ZiKV infection * means of administration, physiological state of the patient, other medications administered, and other factors.
  • the vaccination or administrat o parameters, the dosing schedule, etc., can. -be determined by routine experimentation.
  • a mammalian subject can initially be given a low dose of the vaccine composition.
  • the dose and/or -the relative amounts of the vaccine composition can be varied while monitoring die immune response.
  • Suitable pharmaeeuricali acceptable carriers for the vaccine .compositions of the present disclosure refers to fluid vehicles that can be injected into a host without significant adverse effects.
  • Suitable pharmaceutically acceptable carriers known in the art include, sterile water, saline, glucose solution, and physiologically acceptable aqueous buffers or solutions, including phosphate-buffered saline.
  • Camera may Include auxiliary agents including,, diluents, stabilizers (i.e., sugars and amino acids), preservatives, wetting agents, emulsifying agents, pH buffering agents, viscosity enhancing additives, colors and the like. Appropriate amounts of the ceils are mixed fth the selected carrier t form the final vaccine composition.
  • all the components of the vaccine can be provided together in one carrier, but if desired, one or more components can be provided in a separate carrier and administered in combination with the other components.
  • the surro ate . oint of vaccination can include the specific anii-Zl V antibod levels (titers), T-ce!l activation (by the JFN-gamma levels) and viremta levels upon virus .challenge.
  • the inveiitors will perform these experiments In rhesus monkeys since they are susceptible to ZIKV infection and display almost all manifestations characteristic of human infection. Additionally, a set of experiments using non-human primates will he performed in order to establish whether the vaccination approach, of the present disclosure protects fetuses form infection and the development of neurologic conditi ons.
  • a phannaceiittcal composition (e.g., an immunogenic composition or a vaccine composition) comprising: cells comprising at leas one vims antigen or a fragment thereof (e.g., at least one Zika virus antigen or a fragment thereof), wherein the cells also express a cytokine, such as (jM ⁇ CSF,
  • the present disclosure also provides a pharmaceutic al composition (e.g., an
  • immunogenic composition or a vaccine composition comprising: cells (1) comprising at. least one fJavivirus antigen (e.g., at least one Zika vims antigen), and (ri) expressing at least one cytokine.
  • fJavivirus antigen e.g., at least one Zika vims antigen
  • the composition further comprises an adjuvant as described above.
  • the pharmaceutic l composition When administered to a subject, the pharmaceutic l composition, elicits or enhance an immune response to a virus (eg., Zika virus).
  • a virus eg., Zika virus
  • the present pharmaceutical composition comprises antigen- presenting cells contacted in viim ox ex vivo with at least One virus antigen.
  • the present invention provides a composition comprising antigen-presenting cells contacted in vitro with nucleic acids encoding at least one virus antigen.
  • the present pharmaceutical composition can be ' useful as vaccine compositions for proptiylactic or therapeutic rrcatoent of a viral infection, such as for preventing or treating Zika virus infection in the subject.
  • the present composi tio is administered to a subject, either alone, or hi combination with, one or more other modalities of therapy.
  • the pharmaceutical composition may further comprise a pharmaceutically acceptabl carrier, diluent, or excipient.
  • a pharmaceutically acceptabl carrier diluent
  • excipient a pharmaceutically acceptabl carrier
  • Pharmaceutically acceptable carriers known i the art include, but are not limited to, sterile water, saline, glucose, dextrose, or buffered solutions. Agents such as diluents, stabilizers (e.g., sugars and amino acids), preservatives, wetting agents, emulsifying agents, pH buffering agents, additives that enhance viscosity, and the like. Preferably, the medium or carrie will produce minimal or no adverse ef ecis.
  • the phamiaceulical composition may further comprise a adjuvant
  • the adjuvant Preferably, the
  • the adjuvant employe provides for increased ini aaogenieity.
  • the adjuvant can be one that provides fa slow release of antigen (e.g., altposome * or it can be an adjuvant that is
  • the adjuvant can be a known adjuvant or other substance that promotes nucleic acid uptake, recruits immune system cells to the site of administration , or facilitates the immune activation of responding l mphoid cells.
  • Adjuvants include, but are not limited to, oil and water emulsions, aluminum hydroxide, grucau, dextran sulfate, iron oxide, sodium alginate, Baeto-Adjuvant, synthetic polymers such as poly amino acids and co-polymers of amino acids, saponin, paraffin oil, arid mummy I d peptide.
  • the adjuvant is comprised of incomplete Preand'S adjuvant (Monianide IS A 51) or Corynebacterram granufosum F40.
  • the vaccine compositions of the invention may further comprise various excipients s adjuvants, carriers, auxiliar substances, modulating agents, and the like,
  • a carrier which is optionally present, is a molecule tliat does not itself induce the production of antibodies harmful to the individual receiving the composition.
  • Suitable carriers are typically large, slowly metabolized niacromolecules such as proteins, polysaccharides, pofylaetic acids, poiygivcollic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes), and inactive virus particles.
  • particulate carriers include those derived from polymethyl methaerylate polymers, as well as raicropafticl.es derived, from poly lactides) and poly(lactide-co-glycolides), known as PLG. See., e.g., Jeffery etai, Pharrn. Res. (1993) 10:362-368; cGee J , e af , J Micfoencapsii!. 14(2): 197-210, 1.997 0'Oagin D T, et ai, Vaccirie 1 1:(2): 149-54,. 1.993.
  • Such carriers are well known to those of ordinary skill the art Additionally, these carriers may function as ininiunostiniulating agents ("adjuvants)
  • the antigen may be conjugated to a bacterial toxoid, such as. toxoid from diphtheria, tetanus, cholera, etc., as well as toxins derived from E coll.
  • a bacterial toxoid such as. toxoid from diphtheria, tetanus, cholera, etc.
  • toxins derived from E coll include, but are not limited to: (1) aluminum salts ⁇ to );, such a - aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc.; (2) oiJ h ater emulsion formulations (with or without other specific imniimostimnlatin agents such as mnramyi peptides (see below) or bacterial cell wall components), such as for example (a) MFS9 (international Publication Ma WO 90/MS37), • contaktng 5% Squaleae, 0,5% Tween 80, and 0.5% Span 85 (optionally containing variou
  • Sti nlo.n.TM may be used or particle generated therefrom such as ISCOMs (ininiunostlniu!ating - complexes); (4) Complete Freunds Adjuvant (CFA) and Incomplete Freunds Adjuvant (If A) (5) cytokines, such as mier!eukras (IL- ⁇ , lL-2, etc), .
  • M-CSF macrophage colony stimulating factor
  • TNF tumor necrosis factor
  • beta cherrtokines MiP, I -alpha, 1-beta Eantes, etc
  • a bacter ial ADP- ribosylating toxin such as a cholera toxin (CT), a pertussis toxin (PT), or an E. coli heat-labile toxin (LT% articular f LT-K63 (where lysine is substituted .
  • CT cholera toxin
  • PT pertussis toxin
  • LT% articular f LT-K63 E. coli heat-labile toxin
  • the dosage and regimen will be d ter in d, at least in part, be determined by tire potenc of the modality, the vaccine delivery employed, the need of the subject.
  • the pharmaceutical compo ition can be dministered m a therapeutically or a
  • prophylactleally effective amount Administering the pharmaceutically acceptable composition of the present Invention to the subject can be carried out using known procedures, and at dosages and for periods of time sufficient to achieve a desired effect.
  • a therapeuticall or prophyiactically effective amount of the pharmaceutical composition can vary according to factors such as the age, sex, and weight of the subject.
  • Dosage regime can be adjusted by one of ordinary skill in the art to elicit the desired innnune response including immune responses that provide therapeutic or prophylactic effects
  • the pharmaceutically acceptable .composition can be administered to the su jec at art suitable s3 ⁇ 4e>
  • the route of administering can be parenteral, intrai iscular, subcutaneous, intradermal, iutraper itoneal, intranasal, intravenous (inditding via an indwelling catheter), via an afferent lymph vessel, or by any other route and die subject's condition.
  • the dose will be administered i «. an amount and for a period of time effective in brid ing about a desired • response, be it eliciting the immune response or the prophylactic or therapeutic treatment of the viral infection and/or symptoms associated therewith,
  • Adi3 ⁇ 4inistering can be properly timed, and can depend on the clinical condition of the subject, the objectives of administering * an r other therapies also being contemplated, or administered, in some embodiments, an initial dose can be administered, and the subject monitored for ati immunological and/or clinical response.
  • Suitable means of immunological monitoring include using patient's pe ipheral blood lymphocyte (PBL ) as tespo.nde.fs,.
  • An immunological reaction also can be determined by a delayed inflammatory response at the site of administering:
  • One or more doses subsequent to the initial dose can be given as appropriate, typically on a monthly, semimonthly, or a weekly basis, until the desired effect is achieved. Thereafter, additional booster or maintenance doses can be gi ve as required, particularly when the immunological or clinical benefit appears to subside.
  • Single or multiple administrations of the present composition can be carried out with cell numbers and treatment being selected by a care provider (p. ⁇ >, a hysician), in certain embodiments, the present cells are a minis ere in a phar aeeutiealiy acceptable carrier,.
  • Suitable carriers can be the growth medium in which the cells were grown, or any suitable buffering med u such, as phosphate buffered saline, The cells can be administered alone or as an adjunct therapy in conjunction with other therapeutics.
  • the present composition is admmisiered sysiemieally, e,g. ? by injection.
  • the pharmaceutical composition ma be in a depot or sustained release formulation.
  • one can administer in a targeted drug- delivery system fo example, in a liposome that is coated with iissiie-speeitlc antibody .
  • the liposomes can be targeted to and taken up selecti vely b the tissue.
  • harm ceutical ⁇ ebmpos oiis may be administered directly, eudoscopiealiy, intratracheally, tntrattwntoraUy, intravenously, intraiesionally, inu'aranscularly, intraperitonealiy, regionally, percutaneously, topically, intrarieriaily. jntravesically, or subetrtaieousjy.
  • Compositions i»ay be a mmisiered. 1, 2,. 3, 4 tone 5, 6. 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 7, IS, 19, 20 or more tim.es, and they may be administered every 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, IB,. 19, 20, 21, 22, 23, 24 hours, or I, 2, 3, 4, 5, 6, 7 days, or L 2, 3, 4, 5 weeks, or L 2, 3, 4 , 5, 6, 7, 8, 9, 10, I L 12 months.
  • compositions can be stored in unit or muiti ⁇ do.se containers, for example, sealed ampoules or vials, as art aqueous solution or as a h ophilized t3 ⁇ 4nt ⁇ ;oJatioji for reconstiiutJon.
  • a therapeutic composition containing an agent of this invention is administered in. a unit dose, for exam le *
  • luiit dose when used in reference to a therapeutic composition, of the present invention refers to physically discrete units Suitable as unitary dosage for the subject, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent; Le., carrier, or vehicle.
  • the presen t pharmaceutical composi tion can he gi ven subsequent to, preceding, or eontemporarieousry with, other therapies including therapies that also elicit an. immoae response in the subject, and/or other antiviral therapies.
  • the subject may previously or concurrently be treated by anti- viral agents, surgery, other forms of immunotherapy, mm- angiogenic agents, and hormonal agents.
  • Such other therapies preferably are provided in. such a way so as not to interfere with the immunogenicity of the compositions of th present invention.
  • immunoassays such as MA, ELISA assays; intracellular staining; T celt assays including for example, !ymplioproliferaiion ⁇ l pfeocyte activation) assays, C L
  • cytotoxic cell assays or by assayin fo T-lymp oeytes specific for the antigen in a sensitized Subject.
  • assays are well known in the art . See, e,g,, Ericfcson et ah, I. Immunol. (.1993) 151:4189-4199; Doe et a ... Eur. 1, Immunol. (1994) 24:2369-2376.
  • Recent methods of measuring cell-niediaied immune response include measurement of intracellular cytokines or cytokine secretion by T-eell populations, or by measurement of -epitope specific T-eells (e.g., by the tetramer technique) (reviewed by cMichael, A. JL and O'Callaghan, C. A., I.Exp. Med.
  • Assays for measuring. an immune response also include the cellular enzyme-l inked immunosorbent assa (cELiSA) assay, plaque reduction neutralization test (FR T), etc.
  • cELiSA cellular enzyme-l inked immunosorbent assa
  • FR T plaque reduction neutralization test
  • cytokines e.g., ⁇ - ⁇ , TN - , and/or XL- 17
  • ELISpet assay to determine ' immune responses.
  • the cytokine ELISPOT Enzyme-Linked ImmunoSPOT
  • the assay has the advantage of detecting only actiy3ted m:ernory T eells and has the ability to detect cytokine release in response to antigen b a single cell thereby permitting direct calculation of responder T cell frequencies.
  • Tire high sensitivity and easy performance, allowing the determination of peptide-reactive T cells without prior in vitro expaiision s makes the ELISPOT assay well suited to monitor T cell responses. Tanguay et al, 1994. Lymphokine Cytokine Res. 13: 259. Carter et al, 1997. Curt.
  • the enzyme- linked inmiunospot (ELISPOT) assay (BD Biosciences) is used to detect and analyze ' individual cells that secrete interferon-gamma (IFN'gamma).
  • the ELISPOT assay is capable of detecting cytokine producing cells from both activated naive arid memory T-cell populations and derives lis specificity and sensitivity b employing high affinity capture and detection antibodies and enzyme-amplification. Additional i form tion regarding the use of ELISPOT assay is provided in I. Immunol. Methods. 20GL 2S4(l-2):59.
  • cells are incubated in the wells of the ELISPOT plate pre-coated with a high-affinity monoclonal antibody to which the cytokine, produced during incubation, will bind. Subsequently, cells are washed away. Areas in which the cytokines have been bound are detected with a combination of biotmyiated anti-cyiokme detection antibodies and ⁇ [>-labeied goat an ti- biotin antibodies. The last step in the assay is the addition of a reagent allowing the precipitation of silver on ( ⁇ revealing the site of cytokine secretion, (i.e., spot formation), Animal models, e,g, min-hutnan primates, are known in the art.
  • the mous is an accepted model for human immune response.
  • Mouse NIC cell response to tumors is an. accepted model for human ' N ' cell response to tumors.
  • mouse T cells are a model for human T cells, mouse dendritic cells (DCs) area model for human DCs.
  • mouse NKT cells are a model for human NKT cells * - mouse innate respoase is an accepied model for human innate response, and so on.
  • Model studies are disclosed, for example, for CD8 - T cells, central memory T cells, and effector memory T cells (see, e.g., Walzer, ef al (2002 ⁇ J. Immunol. 168:2704- 2711); the two subsets of NK cells (see, e.g..).
  • Mouse innate response including the Toll-Like Receptors (TLRs) is a model for human innate immune response, as disclosed (see, e,g., Janssens arid Beyaert (2003) Clinical M-icrob, Revs, 16:637- 6 6), M use neutrophils are an accepted model Cor fcumaft nean3 ⁇ 4phik (see, e, ⁇ Kohayashl etal. (2003) Proc. Natl Acad. Sci. USA 100: 10948- 10953; Torres, etal. (2004) 72:2131-2139; Sibelius, et al, (1999) Infection Immunity 67; 1.125-1 BO; Tvinnerei , et al. (2004) J.
  • TLRs Toll-Like Receptors
  • Murine immune response to Listeria is an accepted mode! for human response to Listeria (see, e.g., Kolb-Maiiter, ei al. (2000) Infection Immunity 68:3680-3688; Brzoza, et al (2004) J. Immunol 173:2641-2651 ).
  • the immunological efficacy of the present me-thods and compositions may be determined based on the Distribution Free Resampling (DFR) method.
  • DFR Distribution Free Resampling
  • Immune responses to vaccines were assessed by harvesting splenoeytes, a source that prov ides cells of the immune sy stem, including T cells and dendritic cells (DCs).
  • splenoeytes a source that prov ides cells of the immune sy stem, including T cells and dendritic cells (DCs).
  • DCs dendritic cells
  • ICS assays involve permea ilmng the splenoeytes, and treating with an antibody that binds cytokines that have accumulated inside the immune cell, where the antibody allows fluorescent tagging. Brefeidin blocks protein transport, and provokes the aceanndation of cytokines within the immune cell.
  • the present disclosure further pertains to a kit containing the present phaHnaeeuticat composition.
  • the kit or container holds an effective amount of a pharmaceutical composition for carrying out the methods or producing the compositions described herein and/or instructions for producing or using the compositions for prophylactic use in, or therapy of, a patient or subject having or suspected of having or at risk of viral infection.
  • the kit may comprise instructions for administering the present composition to a subject having ot at risk of viral infection (e,g. Zika virus infection).
  • the instructions will generally Include information abont the use of the composition for the treatment or prevention of viral infection (e + g, , Zika virus . , infection ⁇ , in other embodiments, the insttue tions include at least one of the fol lo wing; description of the therapeutic agent s dosage schedule and ad inistration for treatment or prevention of viral infection or symptoms thereof; precautions; warnings;
  • kits may also contain instructions for combining the components so as to formulate an
  • kits can comprise various components of the pharmaceutical composition or vaccines thereof provided in separate containers as well as various other active ingredients or agents.
  • ike subject is any living organism in which an immune response can be elicited.
  • Subjects include, without limitation;, humans, livestock, dogs, cats, ice, rats, and transgenic species thereof.
  • the kit comprises- a sterile container that contains a therapeutic or prophylactic composition; such containers can ' be ' boxes, ampules, bottles, vials, tubes, bags, pouches, blister-packs, or other suitable container forms known in the art, Such containers can be made of plastic,, glass * ' laminated paper, metal foil, or oilier materials suitabl e for holding medicaments,
  • attenuation and “attenuated” encompasses a virus, or gene in the vims, and the like, that is modified to reduce toxicity to a host.
  • the host can be a human or animal host, of an organ, tissue, of cell.
  • the virus can be attenuated, to reduce binding to a host cell, to reduce spread from one host cell to another host cell, of to reduce intracellular growth in a host ceil, Attenuation- can be assessed by easurin , e, : g:., an indicator of toxicity, the L3 ⁇ 4>, the fate of clearance fr m an gan, or the competitive index (see, e,g, y Auefbueh, et at- (2001 ⁇ infect. Immunit 69:5953-5957).
  • an attenuation results art increase in the LDje by at least 25%; more generally by at least 50%; most generally by at least 100% (2-fold); ' normally by at least 5-fold; more normally by at least 10-fold; most normally by at least 50-fold; often b at least lOO-ibld: more often by ai least 500-fbld; and most ften: by at least 1000- fold; usually at least 5000-fold; more usually by at least 10,000-fold; and most usually by at least 50,000-fold; and most ofte by at least 100,000-ibid
  • "Attenuated gene 4* encompasses a gene that mediates toxicity, pathology, or virulence, to a host, growth within the host, or survival within the host, where the gene is mutated i a way that mitigates, reduces, or eliminates the toxicity, pathology, or virulence.
  • “Mutated gene” encompasses deletions, point mutations, insertion mutations, and frameshift .
  • Effective amount* as used in treatment encompasses:, without limitation, an amount that can ameliorate, reverse, mitigate, or prevent a symptom or sign of a medicai condition or disorder. Unless dictated otherwise, explicitl or otherwise, ai "effecti e amount” is not limited to a minimal amount sufficient to ameliorate a condition, or to an amount that results In an optimal or a maximal amelioration of the condition.
  • an "effective amount" of a vaccine composition or as immunogenic composition refers to the amount of target antigen which elicits measurable immune response in a mammalian subject as compared to the mmu e response in the manunaiian subject in the absence of adminisu ation of the antigen.
  • a subject is a mammal such as a primate, and, more preferably, a human .
  • a mammal such as a primate, and, more preferably, a human .
  • non-human pr imates include marmosets, monkeys, chimpanzees, gorillas, orangutans, and gibbons.
  • subject also includes domesticated animals, such as cats, dogs, etc , livestock (for e ample s cattle (cows), horses, pigs, sheep, goats, etc.), laboratory animals (for example, ferret, -chinchilla, mouse, rabbit, rat, gerhi!, guinea pig, etc.) and avian species (for example, chickens, turkeys, duc s, pheasants, pigeons, doves, parrots, cockatoos, geese, etc.).
  • Subjects can also include fish (for example, zebratish, goldfish, tilapia, salmon, and trout), amphibians and reptiles..
  • a. "subject” is the same as a "patient,” and the ter s can be used interchangeably .
  • control or “reference” is meant a standard of comparison.
  • “changed as compared to 3 ⁇ 4 control” sample or subject Is understood as having a level that is statistically different than a sample from a normal, untreated, or control sample:.
  • Control samples include, fo example, cells in -culture,, one or more laboratory test anim ls, or one or more -human, subjects. Methods to select and test control samples are within the ability of those in the art.
  • operably linked is understood as joined, preferably by a coval ent linkage, e.g though joining an arnino-terminus of one peptide, e,g ⁇ , expressing an enzyme, to a carboxy teeuinus of another peptide, e.g. , expressing a signal sequence to target the protein to a specific cellular eompartrnent; joining a promoter sequence with a protein coding sequence, in manner that the two ormore eomponeins that are operably linked either retain their original activity, or gain at) activity ijponjoirung such that the activity of the operably linked portions can be assay ed and have detectable activity, e.g.. enzymatic activity, protein expression activity.
  • WCV Whole-cell vaccination against ZIKV is produced using irradiated human cancer cells., whic can be infected with the- virus and which can also be genetically modified to express and secrete cytokines that promote antigen, presenting eelfe to engulf vims ⁇ lniee3 ⁇ 4d eells, process the viral antigens, and present them to T-cells.
  • pancreas yaecine is com rise of biun n pancfeat e cattcer cell lines transfected with GM-CSF. For pancreatic cancer treatment, these cells are grown in vitro, irradiated by gamma-rays and administered intradennally as a therapeutic vaccine.
  • GVA expressing GM-CSF is capable of inducing a robust humoral and T-cell response against pancreatic tumors in viva.
  • the inventors will first test permissivity (permissiveness) of GVAX pancreas cells (PANC 6.03-PANC-10.05-G -CSF) to support Z KV infection, in parallel, the inventor will evaluate p rmissivSty of GV AX pancreas ceils to ZIK infection to the cell ' lines known to be pemiissive to ZIK T .
  • permissivity permissiveness
  • pemiissiviiy of GVA cells can be evaluated using a number of techniques, including RT-PCR, ZIKV plaque assay, MOX and/or flow cytometry using ant - ZiK antibody 4G2.
  • a mouse epithelial cell line (that will be used for the generation of the ccin and the tested it in the preclinical animal model) will also be selected based on its capabilitiesit to support the virus. Once identified, such mouse epithelial cell line will be transfected with murine G -
  • the inventors will measure various parameters, including, but not limited to, ami-ZIKV antibody titers, T-eeJl activation (ELISPOT) and . inhibition of infection .in vitro using immune serum.
  • ami-ZIKV antibody titers T-eeJl activation (ELISPOT)
  • ELISPOT T-eeJl activation
  • the levels of anti-ZIKV neutralizing antibodies as well as the levels of T ⁇ celf response will be assessed in vitro using ELISA, plague neutralization assay, ELISPOT and/or other hnmunological techniques.
  • the inventors will use a mouse model wherein animals will be vaccinated with a vaccine derived, from ZIKA. virus permissive mouse cell line and transfected with mGM ⁇ CSF:,
  • GM-CSF Vero rtansieeted cells which will be either in fected with i ka virus or transfected with Zika replieon.
  • animals will be challenged with Zika vims.
  • the vireoria will be monitored in vaccinated animals and compared to non-vaccinated group.
  • the effect of repeating infection will also be evaluated.
  • the inventors will also asses the effectiveness of vaccine composition described here in a developing embryo and/or fetus. For example, adult animals will be vaccinated and allowed, to breed. During the gestation period, animals will be challenged with Zika vims and newborns will be examined, fo the persistence of the virus in their body and for the neurologic manifestation of the viral Infection.
  • this experimental desig is to test whether the initial viremia, which is created by a niosquito bite, can be quenched at the onset of infectio by the existing an i-viral inmumity .
  • the follo ing- general steps will be carried out in moose studies * ( 1 ) permissive .mouse epithelial cancer cell line will be permanently transfected with mouse GM-C F; (2) a fraction of • transfected cells will be infected with Zika virus fo 24-48 ho «rs :S followed by irradiation where the infected cells will be irradiated at, e.g., 25-40 kGy (or other doses as discussed herein) and non-infected, cells at 150-250 Gy ⁇ Subsequent to irradiation, cells will be combined and injected intradermal ⁇ ' in mouse flanks; (3) after three weeks of incubation period, the procedure described in step (2) will be repeated and 8- 10 clays later blood
  • both vaccinated and non-vaccinated mice will be challenged in parallel, and the levels of viremia in blood will be .monitored for- period of time spanning from several days to several weeks,.
  • mice Bell et al. Arch. Intele V irosf tseh. 35, 183-193 (J 97 ); Dick et ai, Tra s . R, Soc Trop, Med. Mm- 46, $09-520 (1952) ⁇ Way et at, I. Gen. Virol. 30, 123-130 (1976)).
  • mice could be infected with ZIKV via intracerebral inoculation, determining mechanisms of pathogenesis and evaluating candidate vaccines requires -more clinically relevant inoculation routes.
  • irsar mice will be injected with in c ivated VAX ceils xpressing GM-GSF, as well as inactivated GVAX cells infected with various strains of ZII V, Vaccination will be carried out at least 2 weeks before challenging the animals with the virus.
  • Vaccination will be carried out at least 2 weeks before challenging the animals with the virus.
  • Ifaarl " * ''" animals that have received the vaec e(s) will he challenged with ZIKV of a specific strain by
  • sabcs:taneo «s (f otp8tl)j intravenous (retro-orbital), or i p. routes with lO; 2 , IQ or ' 10 FFU of ZlKV. Survival, weight toss, and disease symptoms will be .monitored for .14-30 days, depending on the experiment. Mice will be euthanized at various days following the viral challenge, and liver, spleen, kidney, testes, brain, and spinal cord will be harvested, weighed, and • homogenized. Viral burden will be evaluated by q T- CR or plaque assay (Lazear et a!. Cell Host Microbe (2016) SI 931-3128(16)30102-0),.
  • Miner et ai have recently described a mouse model of placental and fetal disease associated with mater ⁇ tr nsmission of ZIK.V (Cell 2016 May 19 165(5); 1081 - 1 ) .
  • WT wild-type
  • maternal inoculation at embryonic day (E6.5) or E7.5 resulted in fetal demise that was associated with Z1KV infection of the placenta and fetal brain.
  • this model can be used, to test ability of vaceioe(s) of the present disc losure to prevent congeni tal malformations during pregnancy.
  • Mouse neuroblastoma cell line N2a was used to ⁇ produce. whale cell-based vaccine against the Zika virus, N2a cells originate from. Baib/C mice and have similar genetic background.
  • the N2a cells were transfected with ONA encoding mouse M-CSF using pcDNA-3.1 vector containing the neo-resistance gene.
  • the transfected ceils were designated as N2a-G SCF of 2a-GM, N2a-GM cells were infecte with 2IKV: strain M&776 (Uganda). Ital Infection was monitored by staining viral B2 protein using arh-B antibodies 4G2 according to the following protocol:
  • a first vaccination or prime vaccination about 1 f cells at th infectivity rate of about 40-50% were injected suhentaraeousiy into the right Sanies of the mice.
  • boosterst For the second (boost) vaccination, about 20x10* cells at the infectivity rate of about 80-90% were injected subeutaneously in the right flanks of the mice.
  • the eELISA. test was performed as follows.
  • Ultra-TMB substrate solution (ThermoFisher, catalog number 34028), 50 ⁇ well, incubate for 1 hr at RT
  • Figure 3 shows antibody response (vertical bars according to the left y-axis, cEOSA assay on N2a-GM-E1KV cells) and antibody neutmliza ion potential (solid line according to the right y-axis, PENT) for three groups of mice immunized with N2a-GM-2iKV cells (group A), ' N2a-ZI Y cells (group B), or purified ZIKV (grou C), respectively , hi the plaque reduction neutralization test (PENT), neutralization of ZIKV virus-fonmng plaques was studied in the presence of sera fjrora mice vaccinated with N2a-GM-ZiKV cells (A) 4 N2a-ZIKV ceils (B), or purified ZIKV (C).
  • anti-Z KV antibody titers are higher in mice immunized w ith 2 -GM-Z3 V than anii-ZK ⁇ antibody titers in mice immunized with N2a- XtKV or purified I .
  • the dilution of sera required for 50% inhibition, of virus induced plaques is the highest in group A which is in good correlation with the antibod titers.
  • Figure 4 shows antibody response (vertical bars according to the left y-axis, cELISA assay on N2a-G -Z1KV cells) for, as well as the number of colonies infected with ZIKV in the presence of a fixed dilution (1 :30£ ) 0) of the serum from, three groups of mice immunized wi h N2a-GM-Z1KV cells (group A N3 ⁇ 4a-Zi V cells (group B) 5 or purified ZIKV (group C ⁇ ⁇ respectively.
  • Figure 4 is similar to Figure 3 except that in, this experiment the number of virus induced plaques was counted at the fixed sera dilution usin sera ires* mice Horn: all three .groups.
  • PRN was used to u ntit the titer of aeiitraiizing aatihod for the ika vims.
  • Sertim r m the vaccinated mice was pretneuhated with th ZIK V to allow the antibodies to react with the viruses.
  • the serurn that had been preincubaied with the ZiKV was then added to a. racmakyer of host cells (e.g., N2A cells, or N2A-GM cells).
  • the concentration of serum to reduce the number of plaques by 50% .compared to the seruin-r ee virus gives the measure of how much antibody is present or how effective it is. This -measurement Is denoted as the PRNT50 value.
  • the dilution of serum to reduce the number of plaques by 50% compared to the serum-free vims gives the measure of how much antibody is present or how effective it is * This measurement is denoted as the 50% neutralization value (Fi ure 3).
  • PRHT was done as follows.
  • the serum was. diluted in series at step 4 starting with 1/25 growth media), and titrate down with step 4 (last dil. ⁇ ;160Q), 60 ⁇ of all dilutions was prepared in triplicates; Several wells with 60 ⁇ ⁇ diluent (media) tor ZiKV only which is added later as a control Single dilution of 1/4 of pre-titrated ZIKV containing media is also prepared.. 60 ui of ZIKV (1:40) are added int all wells with, ser ;, normal mouse serum (NMS) and culture media. The final dilution of sera in preincubation plate increases 2 times and becomes the range fro 1/50 to 1/3200. The plate is incubated on a plate shaker at 2500 rprn for 2 hrs at room temperature.
  • Figures 5 A md SB N2a-GMCSF cells ( Figures S and SF), N2a new cell line ( Figures 5G arid 5H), human fibroblasts WS-1 ( Figures 51 and Sj), human fibroblasts PC S2 ( ) 1-012 ( Figure SK), were infected with IK V-contaioittg cell culture media (P2) aad itnmunostained using a «ti.-E2 antibodies 4G2 at different time pcnnts post ⁇ infectk>m e ⁇ .g., 24 hours, or 48 hou s postinfection * The cells were immunostaked for the virus E2 antigen using anii-E2 antibodies 4G2 (see
  • Example 3 for the staining protocol show different levels of peoiiissivit of cells for ZIKV infection.
  • a multiplicity of infection ( ⁇ ) 1 the highly .remissive cell line is Vero (90- 100%),. while human fibroblasts and N2 cells have tow petratssivity (3-5%).
  • MOl 20 was used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention porte sur des cellules incapables de prolifération pour administrer des virus Zika inactivés et des GM-CSF à un sujet, et pour induire ou renforcer les réponses immunitaires humorales et cellulaires contre les antigènes du virus Zika.
PCT/US2017/038340 2016-06-21 2017-06-20 Vaccin à base de cellules complètes contre le virus zika WO2017223090A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662352796P 2016-06-21 2016-06-21
US62/352,796 2016-06-21

Publications (1)

Publication Number Publication Date
WO2017223090A1 true WO2017223090A1 (fr) 2017-12-28

Family

ID=60783367

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/038340 WO2017223090A1 (fr) 2016-06-21 2017-06-20 Vaccin à base de cellules complètes contre le virus zika

Country Status (1)

Country Link
WO (1) WO2017223090A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023137370A3 (fr) * 2022-01-13 2023-09-28 Orgenesis Inc. Vaccins contre le sars-cov-2 à base de cellules autologues

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US20050002916A1 (en) * 2003-04-02 2005-01-06 Karin Jooss Cytokine-expressing cellular vaccine combinations
US20110020393A1 (en) * 2007-12-26 2011-01-27 The Kitasato Institute Method of Producing Japanese Encephalitis Vaccine Stably Storable Over Long Time and Use of the Vaccine
US20120003255A1 (en) * 2010-07-01 2012-01-05 Research Development Foundation Flavivirus host-range mutations and uses thereof
WO2013138670A1 (fr) * 2012-03-15 2013-09-19 Icahn School Of Medicine At Mount Sinai Mutants ns5 du virus de la fièvre jaune en tant que candidats vaccinaux contre le flavivirus
US20130315952A1 (en) * 2009-06-09 2013-11-28 Defyrus, Inc. Administration of interferon for prophylaxis against or treatment of pathogenic infection
US20170014502A1 (en) * 2015-07-16 2017-01-19 Bharat Biotech International Limited Vaccine compositions

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US20050002916A1 (en) * 2003-04-02 2005-01-06 Karin Jooss Cytokine-expressing cellular vaccine combinations
US20110020393A1 (en) * 2007-12-26 2011-01-27 The Kitasato Institute Method of Producing Japanese Encephalitis Vaccine Stably Storable Over Long Time and Use of the Vaccine
US20130315952A1 (en) * 2009-06-09 2013-11-28 Defyrus, Inc. Administration of interferon for prophylaxis against or treatment of pathogenic infection
US20120003255A1 (en) * 2010-07-01 2012-01-05 Research Development Foundation Flavivirus host-range mutations and uses thereof
WO2013138670A1 (fr) * 2012-03-15 2013-09-19 Icahn School Of Medicine At Mount Sinai Mutants ns5 du virus de la fièvre jaune en tant que candidats vaccinaux contre le flavivirus
US20170014502A1 (en) * 2015-07-16 2017-01-19 Bharat Biotech International Limited Vaccine compositions

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DAWES ET AL.: "Research and Development of Zika Virus Vaccines", NPJ VACCINES, vol. 1, no. 16007, 28 June 2016 (2016-06-28), pages 1 - 7, XP055331389 *
HAMEL ET AL.: "Biology of Zika Virus Infection in Human Skin Cells", JOURNAL OF VIRIOLOGY, vol. 89, no. 17, 17 June 2015 (2015-06-17), pages 8880 - 8896, XP002769770 *
KRISHNAN, V.: "Bharat Biotech Seeks Govt. Approval of Two Zika Vaccine Candidates", THE HINDU, 3 February 2016 (2016-02-03), pages 1 - 2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023137370A3 (fr) * 2022-01-13 2023-09-28 Orgenesis Inc. Vaccins contre le sars-cov-2 à base de cellules autologues

Similar Documents

Publication Publication Date Title
Flatz et al. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity
Kanagavelu et al. Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine
Davenport et al. Chikungunya virus evades antiviral CD8+ T cell responses to establish persistent infection in joint-associated tissues
EP1765402A2 (fr) Methodes et compositions ameliorant l'immunite par depletion in vivo de l'activite cellulaire immunosuppressive
Muthumani et al. Co‐immunization with an optimized plasmid‐encoded immune stimulatory interleukin, high‐mobility group box 1 protein, results in enhanced interferon‐γ secretion by antigen‐specific CD8 T cells
Niezold et al. DNA vaccines encoding DEC 205‐targeted antigens: immunity or tolerance?
KR20220116191A (ko) 4-1bbl 아쥬반트화 재조합 변형 백시니아 바이러스 앙카라 (mva)의 의약적 용도
JP6273290B2 (ja) 疾患の処置のための同種異系のオートファゴソーム強化組成物
Seighali et al. Human T-cell lymphotropic virus type 1 (HTLV-1) proposed vaccines: a systematic review of preclinical and clinical studies
Tian et al. Enhancement of the immunogenicity of an alphavirus replicon-based DNA vaccine against classical swine fever by electroporation and coinjection with a plasmid expressing porcine interleukin 2
Santana et al. Advances in preventive vaccine development against HTLV-1 infection: A systematic review of the last 35 years
Woo et al. Co‐administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG‐oligodeoxynucleotide induces potent antitumor immunity
Shi et al. The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization
Sordo et al. Humoral and cellular immune response in mice induced by the classical swine fever virus E2 protein fused to the porcine CD154 antigen
Gülçe İz et al. Co-expression of the Bcl-xL antiapoptotic protein enhances the induction of Th1-like immune responses in mice immunized with DNA vaccines encoding FMDV B and T cell epitopes
Langellotti et al. Foot-and-mouth disease virus causes a decrease in spleen dendritic cells and the early release of IFN-α in the plasma of mice. Differences between infectious and inactivated virus
Mackenzie-Dyck et al. Immunogenicity of a bovine herpesvirus 1 glycoprotein D DNA vaccine complexed with bovine neutrophil beta-defensin 3
WO2017223090A1 (fr) Vaccin à base de cellules complètes contre le virus zika
AU2013262426A1 (en) Cellular vaccine and method of inducing an immune response in a subject
He et al. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge
Lee et al. Combination adjuvants affect the magnitude of effector-like memory CD8 T cells and protection against listeriosis
Gottrand et al. Intrathymic injection of lentiviral vector curtails the immune response in the periphery of normal mice
Zhai et al. The dominant roles of ICAM-1-encoding gene in DNA vaccination against Japanese encephalitis virus are the activation of dendritic cells and enhancement of cellular immunity
Calarota et al. Augmentation of SIV DNA vaccine-induced cellular immunity by targeting the 4-1BB costimulatory molecule
Manfredi et al. Induction of SARS-CoV-2 N-specific CD8+ T cell immunity in lungs by engineered extracellular vesicles associates with strongly impaired viral replication

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17816064

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17816064

Country of ref document: EP

Kind code of ref document: A1